{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:58:57Z","timestamp":1789912737819,"version":"4.0.1"},"reference-count":48,"publisher":"Aboutscience Srl","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Circ Biomark"],"abstract":"<jats:p>Introduction: Anti-centromere antibodies are associated with limited cutaneous systemic sclerosis (lcSSc) anda more favorable prognosis. The centromere HEp-2 pattern (AC-3) suggests the presence of antibodies againstCENP antigens, mainly CENP-B\/A. This study analyzed clinical and demographic associations of anti-centromereantibodies in a cohort of patients exclusively with the lcSSc form of SSc. The frequency of CENP-B and CENP-Areactivity in samples with the AC-3 pattern was also evaluated.Method: Samples from 38 lcSSc patients with AC-3 were evaluated for reactivity to CENP-B\/A using line-blot andELISA. Clinical data from 68 lcSSc patients (20 AC-3 and 48 Non-AC-3) were analyzed.Results: Of the AC-3 samples, 84% and 82% were reactive against CENP-B and CENP-A, respectively, by line-blot,and 92% were positive for CENP-B by ELISA. Concordance for CENP-B reactivity between ELISA and line-blot was79%. Reactivity to both CENP-B and CENP-A was found in 68% of AC-3 samples, while one sample was positiveonly for CENP-A. Overall, 97% of AC-3 samples were reactive to CENP-B, and all were reactive to either CENP-B orCENP-A. Clinically, interstitial lung disease (ILD) was less frequent in AC-3 patients compared to Non-AC-3 (10.5%vs. 54.2%; p = 0.001). Other organ involvement frequencies were similar.Conclusion: ILD was less frequent in lcSSc patients with a positive AC-3 pattern as compared to those with anon-AC-3 pattern, which could suggest a less severe prognosis. In addition, anti-CENP-B was the predominantautoantibody in samples yielding the AC-3 pattern, but anti-CENP-A reactivity was also prevalent, and exclusiveanti-CENP-A reactivity was also observed.<\/jats:p>","DOI":"10.33393\/jcb.2025.3608","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:17:55Z","timestamp":1764170275000},"page":"54-63","source":"Crossref","is-referenced-by-count":1,"title":["Anti-CENP-A\/B reactivity in samples exhibiting the centromere HEp-2 pattern is associated with a lower frequency of interstitial lung disease in limited cutaneous systemic sclerosis patients"],"prefix":"10.33393","volume":"14","author":[{"given":"Gerson D","family":"Keppeke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Landoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiane","family":"Kayser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Matos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Diogenes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Keppeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Helena","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Eduardo C.","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18642","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"18003","doi-asserted-by":"crossref","unstructured":"Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685-1699. https:\/\/doi.org\/10.1016\/S0140-6736(17)30933-9 PMID:28413064","DOI":"10.1016\/S0140-6736(17)30933-9"},{"key":"18004","doi-asserted-by":"crossref","unstructured":"Roofeh D, Khanna D. Management of systemic sclerosis: the first five years. Curr Opin Rheumatol. 2020;32(3):228-237. https:\/\/doi.org\/10.1097\/BOR.0000000000000711 PMID:32205570","DOI":"10.1097\/BOR.0000000000000711"},{"key":"18005","doi-asserted-by":"crossref","unstructured":"Stochmal A, Czuwara J, Trojanowska M, et al. Antinuclear antibodies in systemic sclerosis: an update. Clin Rev Allergy Immunol. 2020;58(1):40-51. https:\/\/doi.org\/10.1007\/s12016-018-8718-8 PMID:30607749","DOI":"10.1007\/s12016-018-8718-8"},{"key":"18006","doi-asserted-by":"crossref","unstructured":"van Leeuwen NM, Boonstra M, Bakker JA, et al. Anticentromere antibody levels and isotypes and the development of systemic sclerosis. Arthritis Rheumatol. 2021;73(12):2338-2347. https:\/\/doi.org\/10.1002\/art.41814 PMID:34042326","DOI":"10.1002\/art.41814"},{"key":"18007","doi-asserted-by":"crossref","unstructured":"Kowalska-K\u0119pczy\u0144ska A. Systemic scleroderma-definition, clinical picture and laboratory diagnostics. J Clin Med. 2022;11(9):2299. https:\/\/doi.org\/10.3390\/jcm11092299 PMID:35566425","DOI":"10.3390\/jcm11092299"},{"key":"18008","doi-asserted-by":"crossref","unstructured":"Johnson SR. New ACR EULAR guidelines for systemic sclerosis classification. Curr Rheumatol Rep. 2015;17(5):32. https:\/\/doi.org\/10.1007\/s11926-015-0506-3 PMID:25874345","DOI":"10.1007\/s11926-015-0506-3"},{"key":"18009","doi-asserted-by":"crossref","unstructured":"van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747-1755. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204424 PMID:24092682","DOI":"10.1136\/annrheumdis-2013-204424"},{"key":"18010","doi-asserted-by":"crossref","unstructured":"Chepy A, Collet A, Launay D, et al. Autoantibodies in systemic sclerosis: from disease bystanders to pathogenic players. J Transl Autoimmun. 2025;10:100272. https:\/\/doi.org\/10.1016\/j.jtauto.2025.100272 PMID:39917316","DOI":"10.1016\/j.jtauto.2025.100272"},{"key":"18011","doi-asserted-by":"crossref","unstructured":"Kajio N, Takeshita M, Suzuki K, et al. Anti-centromere antibodies target centromere-kinetochore macrocomplex: a comprehensive autoantigen profiling. Ann Rheum Dis. 2021;80(5):651-659. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218881 PMID:33208344","DOI":"10.1136\/annrheumdis-2020-218881"},{"key":"18012","doi-asserted-by":"crossref","unstructured":"Koenig M, Joyal F, Fritzler MJ, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum. 2008;58(12):3902-3912. https:\/\/doi.org\/10.1002\/art.24038 PMID:19035499","DOI":"10.1002\/art.24038"},{"key":"18013","doi-asserted-by":"crossref","unstructured":"Reveille JD, Solomon DH.; American College of Rheumatology Ad Hoc Committee of Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum. 2003;49(3):399-412. https:\/\/doi.org\/10.1002\/art.11113 PMID:12794797","DOI":"10.1002\/art.11113"},{"key":"18014","doi-asserted-by":"crossref","unstructured":"Hudson M, Mahler M, Pope J, et al.; Investigators of the Canadian Scleroderma Research Group. Clinical correlates of CENP-A and CENP-B antibodies in a large cohort of patients with systemic sclerosis. J Rheumatol. 2012;39(4):787-794. https:\/\/doi.org\/10.3899\/rheum.111133 PMID:22467948","DOI":"10.3899\/rheum.111133"},{"key":"18015","doi-asserted-by":"crossref","unstructured":"Matos P, Keppeke GD, Kayser C. Autoanticorpos espec\u00edficos e associados na esclerose sist\u00eamica: investiga\u00e7\u00e3o e diagn\u00f3stico. Revista Paulista de Reumatologia. 2024;23(3):41-50. https:\/\/doi.org\/10.46833\/reumatologiasp.2024.23.3.41-50","DOI":"10.46833\/reumatologiasp.2024.23.3.41-50"},{"key":"18016","doi-asserted-by":"crossref","unstructured":"Chan EKL, Damoiseaux J, Carballo OG, et al. Report of the First International Consensus on standardized nomenclature of antinuclear antibody HEp-2 cell patterns 2014-2015. Front Immunol. 2015;6:412. https:\/\/doi.org\/10.3389\/fimmu.2015.00412 PMID:26347739","DOI":"10.3389\/fimmu.2015.00412"},{"key":"18017","doi-asserted-by":"crossref","unstructured":"Andrade LEC, Klotz W, Herold M, et al. Reflecting on a decade of the international consensus on ANA patterns (ICAP): accomplishments and challenges from the perspective of the 7th ICAP workshop. Autoimmun Rev. 2024;23(9):103608. https:\/\/doi.org\/10.1016\/j.autrev.2024.103608 PMID:39187221","DOI":"10.1016\/j.autrev.2024.103608"},{"key":"18018","doi-asserted-by":"crossref","unstructured":"Akbarali Y, Matousek-Ronck J, Hunt L, et al. Fine specificity mapping of autoantigens targeted by anti-centromere autoantibodies. J Autoimmun. 2006;27(4):272-280. https:\/\/doi.org\/10.1016\/j.jaut.2006.10.001 PMID:17210244","DOI":"10.1016\/j.jaut.2006.10.001"},{"key":"18019","doi-asserted-by":"crossref","unstructured":"Prasad RM, Bellacosa A, Yen TJ. Clinical and Molecular Features of Anti-CENP-B Autoantibodies. J Mol Pathol. 2021;2(4):281-295. https:\/\/doi.org\/10.3390\/jmp2040024","DOI":"10.3390\/jmp2040024"},{"key":"18020","doi-asserted-by":"crossref","unstructured":"Earnshaw WC, Rothfield N. Identification of a family of human centromere proteins using autoimmune sera from patients with scleroderma. Chromosoma. 1985;91(3-4):313-321. https:\/\/doi.org\/10.1007\/BF00328227 PMID:2579778","DOI":"10.1007\/BF00328227"},{"key":"18021","doi-asserted-by":"crossref","unstructured":"Earnshaw W, Bordwell B, Marino C, et al. Three human chromosomal autoantigens are recognized by sera from patients with anti-centromere antibodies. J Clin Invest. 1986;77(2):426-430. https:\/\/doi.org\/10.1172\/JCI112320 PMID:3511098","DOI":"10.1172\/JCI112320"},{"key":"18022","doi-asserted-by":"crossref","unstructured":"Muro Y, Azuma N, Onouchi H, et al. Autoepitopes on autoantigen centromere protein-a (CENP-A) are restricted to the N-terminal region, which has no homology with histone H3. Clin Exp Immunol. 2000;120(1):218-223. https:\/\/doi.org\/10.1046\/j.1365-2249.2000.01189.x PMID:10759786","DOI":"10.1046\/j.1365-2249.2000.01189.x"},{"key":"18023","doi-asserted-by":"crossref","unstructured":"Mahler M, Fritzler MJ. Epitope specificity and significance in systemic autoimmune diseases. Ann N Y Acad Sci. 2010;1183(1):267-287. https:\/\/doi.org\/10.1111\/j.1749-6632.2009.05127.x PMID:20146721","DOI":"10.1111\/j.1749-6632.2009.05127.x"},{"key":"18024","doi-asserted-by":"crossref","unstructured":"Fritzler MJ, Rattner JB, Luft LM, et al. Historical perspectives on the discovery and elucidation of autoantibodies to centromere proteins (CENP) and the emerging importance of antibodies to CENP-F. Autoimmun Rev. 2011;10(4):194-200. https:\/\/doi.org\/10.1016\/j.autrev.2010.09.025 PMID:20933614","DOI":"10.1016\/j.autrev.2010.09.025"},{"key":"18025","doi-asserted-by":"crossref","unstructured":"Damoiseaux J, Andrade LEC, Carballo OG, et al. Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. Ann Rheum Dis. 2019;78(7):879-889. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214436 PMID:30862649","DOI":"10.1136\/annrheumdis-2018-214436"},{"key":"18026","doi-asserted-by":"crossref","unstructured":"Keppeke GD, Agustinelli RA, Landoni DM, et al. Chapter 88 - Future Direction of Laboratory Testing for Autoimmune Diseases. In: Schmitz JL, Detrick B, O'Gorman MRG, editors. Manual of Molecular and Clinical Laboratory Immunology, 9th Edition. 2. 9 ed. Washington, DC: Wiley & ASM Press; 2024. p. 968-82. https:\/\/doi.org\/10.1002\/9781683674023.ch88","DOI":"10.1002\/9781683674023.ch88"},{"key":"18027","doi-asserted-by":"crossref","unstructured":"Mahler M, You D, Baron M, et al.; Canadian Scleroderma Research Group (CSRG). Anti-centromere antibodies in a large cohort of systemic sclerosis patients: comparison between immunofluorescence, CENP-A and CENP-B ELISA. Clin Chim Acta. 2011;412(21-22):1937-1943. https:\/\/doi.org\/10.1016\/j.cca.2011.06.041 PMID:21756890","DOI":"10.1016\/j.cca.2011.06.041"},{"key":"18028","doi-asserted-by":"crossref","unstructured":"Keppeke GD, Satoh M, Kayser C, et al. A cell-based assay for detection of anti-fibrillarin autoantibodies with performance equivalent to immunoprecipitation. Front Immunol. 2022;13:1011110. https:\/\/doi.org\/10.3389\/fimmu.2022.1011110 PMID:36225928","DOI":"10.3389\/fimmu.2022.1011110"},{"key":"18029","doi-asserted-by":"crossref","unstructured":"Sowa M, Hiemann R, Schierack P, et al. Next-generation autoantibody testing by combination of screening and confirmation\u2014the CytoBead\u00ae Technology. Clin Rev Allergy Immunol. 2017;53(1):87-104. https:\/\/doi.org\/10.1007\/s12016-016-8574-3 PMID:27368807","DOI":"10.1007\/s12016-016-8574-3"},{"key":"18030","doi-asserted-by":"crossref","unstructured":"Jang J, Kim S, Kim HS, et al. Comparison of antinuclear antibody profiles obtained using line immunoassay and fluorescence enzyme immunoassay. J Int Med Res. 2021;49(6):3000605211014390. https:\/\/doi.org\/10.1177\/03000605211014390 PMID:34154430","DOI":"10.1177\/03000605211014390"},{"key":"18031","doi-asserted-by":"crossref","unstructured":"de Oliveira SM, Martins LVO, Lupino-Assad AP, et al. Severity and mortality of COVID-19 in patients with systemic sclerosis: a Brazilian multicenter study. Semin Arthritis Rheum. 2022;55:151987. https:\/\/doi.org\/10.1016\/j.semarthrit.2022.151987 PMID:35286906","DOI":"10.1016\/j.semarthrit.2022.151987"},{"key":"18032","doi-asserted-by":"crossref","unstructured":"Kayser C, de Oliveira Delgado SM, Zimmermann AF, et al. 2023 Brazilian Society of Rheumatology guidelines for the treatment of systemic sclerosis. Adv Rheumatol. 2024;64(1):52. https:\/\/doi.org\/10.1186\/s42358-024-00392-w PMID:38987832","DOI":"10.1186\/s42358-024-00392-w"},{"key":"18033","doi-asserted-by":"crossref","unstructured":"Humbert M, Kovacs G, Hoeper MM, et al.; ESC\/ERS Scientific Document Group. 2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61(1):2200879. https:\/\/doi.org\/10.1183\/13993003.00879-2022 PMID:36028254","DOI":"10.1183\/13993003.00879-2022"},{"key":"18034","doi-asserted-by":"crossref","unstructured":"\u017bebryk P, Przymusza\u0142a P, Nowak JK, et al. Autoantibodies and clinical correlations in Polish systemic sclerosis patients: a cross-sectional study. J Clin Med. 2023;12(2):657. https:\/\/doi.org\/10.3390\/jcm12020657 PMID:36675584","DOI":"10.3390\/jcm12020657"},{"key":"18035","doi-asserted-by":"crossref","unstructured":"Fritzler MJ, Kinsella TD, Garbutt E. The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med. 1980;69(4):520-526. https:\/\/doi.org\/10.1016\/0002-9343(80)90462-3 PMID:6968511","DOI":"10.1016\/0002-9343(80)90462-3"},{"key":"18036","doi-asserted-by":"crossref","unstructured":"Moroi Y, Peebles C, Fritzler MJ, et al. Autoantibody to centromere (kinetochore) in scleroderma sera. Proc Natl Acad Sci USA. 1980;77(3):1627-1631. https:\/\/doi.org\/10.1073\/pnas.77.3.1627 PMID:6966403","DOI":"10.1073\/pnas.77.3.1627"},{"key":"18037","doi-asserted-by":"crossref","unstructured":"Tan EM, Rodnan GP, Garcia I, et al. Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum. 1980;23(6):617-625. https:\/\/doi.org\/10.1002\/art.1780230602 PMID:6155920","DOI":"10.1002\/art.1780230602"},{"key":"18038","doi-asserted-by":"crossref","unstructured":"Saito A, Muro Y, Sugiura K, et al. CENP-O, a protein localized at the centromere throughout the cell cycle, is a novel target antigen in systemic sclerosis. J Rheumatol. 2009;36(4):781-786. https:\/\/doi.org\/10.3899\/jrheum.080726 PMID:19286853","DOI":"10.3899\/jrheum.080726"},{"key":"18039","doi-asserted-by":"crossref","unstructured":"Earnshaw WC, Machlin PS, Bordwell BJ, et al. Analysis of anticentromere autoantibodies using cloned autoantigen CENP-B. Proc Natl Acad Sci USA. 1987;84(14):4979-4983. https:\/\/doi.org\/10.1073\/pnas.84.14.4979 PMID:2440036","DOI":"10.1073\/pnas.84.14.4979"},{"key":"18040","unstructured":"Ford AL, Kurien BT, Harley JB, et al. Anti-centromere autoantibody in a patient evolving from a lupus\/Sj\u00f6gren's overlap to the CREST variant of scleroderma. J Rheumatol. 1998;25(7):1419-1424. PMID:9676778"},{"key":"18041","doi-asserted-by":"crossref","unstructured":"Rattner JB, Rees J, Arnett FC, et al. The centromere kinesin-like protein, CENP-E. An autoantigen in systemic sclerosis. Arthritis Rheum. 1996;39(8):1355-1361. https:\/\/doi.org\/10.1002\/art.1780390813 PMID:8702444","DOI":"10.1002\/art.1780390813"},{"key":"18042","doi-asserted-by":"crossref","unstructured":"Hsu TC, Chang CH, Lin MC, et al. Anti-CENP-H antibodies in patients with Sj\u00f6gren's syndrome. Rheumatol Int. 2006;26(4):298-303. https:\/\/doi.org\/10.1007\/s00296-004-0568-4 PMID:15700116","DOI":"10.1007\/s00296-004-0568-4"},{"key":"18043","doi-asserted-by":"crossref","unstructured":"Casiano CA, Landberg G, Ochs RL, et al. Autoantibodies to a novel cell cycle-regulated protein that accumulates in the nuclear matrix during S phase and is localized in the kinetochores and spindle midzone during mitosis. J Cell Sci. 1993;106(Pt 4):1045-1056. https:\/\/doi.org\/10.1242\/jcs.106.4.1045 PMID:7907337","DOI":"10.1242\/jcs.106.4.1045"},{"key":"18044","doi-asserted-by":"crossref","unstructured":"Landberg G, Erlanson M, Roos G, et al. Nuclear autoantigen p330d\/CENP-F: a marker for cell proliferation in human malignancies. Cytometry. 1996;25(1):90-98. https:\/\/doi.org\/10.1002\/(SICI)1097-0320(19960901)25:1<90::AID-CYTO10>3.0.CO;2-P PMID:8875058","DOI":"10.1002\/(SICI)1097-0320(19960901)25:1<90::AID-CYTO10>3.0.CO;2-P"},{"key":"18045","unstructured":"Rattner JB, Rees J, Whitehead CM, et al. High frequency of neoplasia in patients with autoantibodies to centromere protein CENP-F. Clin Invest Med. 1997;20(5):308-319. PMID:9336656"},{"key":"18046","doi-asserted-by":"crossref","unstructured":"Welner S, Trier NH, Frisch M, et al. Correlation between centromere protein-F autoantibodies and cancer analyzed by enzyme-linked immunosorbent assay. Mol Cancer. 2013;12(1):95. https:\/\/doi.org\/10.1186\/1476-4598-12-95 PMID:23978088","DOI":"10.1186\/1476-4598-12-95"},{"key":"18047","doi-asserted-by":"crossref","unstructured":"Bossuyt X, Fieuws S. Detection of antinuclear antibodies: added value of solid phase assay? Ann Rheum Dis. 2014;73(3):e10. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204793 PMID:24257025","DOI":"10.1136\/annrheumdis-2013-204793"},{"key":"18048","doi-asserted-by":"crossref","unstructured":"Pisetsky DS, Lipsky PE. Role of antinuclear antibody determinations in classification criteria for systemic lupus erythematosus: comment on the article by Leuchten et al. Arthritis Care Res (Hoboken). 2019;71(5):696. https:\/\/doi.org\/10.1002\/acr.23559 PMID:29579355","DOI":"10.1002\/acr.23559"},{"key":"18049","doi-asserted-by":"crossref","unstructured":"de Oliveira Martins LV, Oliveira SM, Silvatti J, et al. Mortality in systemic sclerosis-associated interstitial lung disease in Brazil: a real-life, long-term follow-up observational study. J Clin Rheumatol. 2022;28(2):e532-e538. https:\/\/doi.org\/10.1097\/RHU.0000000000001792 PMID:34609336","DOI":"10.1097\/RHU.0000000000001792"},{"key":"18050","doi-asserted-by":"crossref","unstructured":"Hoffmann-Vold AM, Petelytska L, Fretheim H, et al. Predicting the risk of subsequent progression in patients with systemic sclerosis-associated interstitial lung disease with progression: a multicentre observational cohort study. Lancet Rheumatol. 2025;7(7):e463-e471. https:\/\/doi.org\/10.1016\/S2665-9913(25)00026-8 PMID:40381640","DOI":"10.1016\/S2665-9913(25)00026-8"}],"container-title":["Journal of Circulating Biomarkers"],"original-title":[],"link":[{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/jcb\/article\/download\/3608\/4149","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/jcb\/article\/download\/3608\/4150","content-type":"application\/epub+zip","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/jcb\/article\/download\/3608\/4148","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/jcb\/article\/download\/3608\/4149","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:18:08Z","timestamp":1764170288000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/jcb\/article\/view\/3608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,6,9]]}},"URL":"https:\/\/doi.org\/10.33393\/jcb.2025.3608","relation":{},"ISSN":["1849-4544","1849-4544"],"issn-type":[{"value":"1849-4544","type":"electronic"},{"value":"1849-4544","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,26]]}}}